Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | SORD | Q00796 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725222 | 0.90 | HTT (0.46) | HTTALDH1A1KDM4EMEN1RAB9A | |
| SCHEMBL4582850 | 0.88 | ALDH1A1 (0.53) | ALDH1A1KDM4EMEN1RAB9AKMT2A | |
| SCHEMBL4583236 | 0.86 | ALDH1A1 (0.54) | ALDH1A1KDM4EMEN1RAB9AKMT2A | |
| SCHEMBL4582247 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KDM4EMEN1RAB9AKMT2A | |
| SCHEMBL4582075 | 0.85 | MALT1 (0.45) | HRH4PHGDHHTR2CMALT1 | |
| SCHEMBL4779994 | 0.83 | MALT1 (0.44) | ALDH1A1KMT2AHRH4MALT1 | |
| SCHEMBL4584076 | 0.83 | PKM (0.54) | ALDH1A1KDM4EMEN1RAB9AKMT2A | |
| SCHEMBL4582822 | 0.83 | ALDH1A1 (0.51) | ALDH1A1KMT2AHRH4HTR2C | |
| SCHEMBL4584337 | 0.83 | MALT1 (0.45) | MEN1KMT2AHRH4PHGDHMALT1 | |
| SCHEMBL4582726 | 0.82 | POLB (0.53) | ALDH1A1RAB9ASMN1; SMN2HRH4PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | PTGER2, PTGER1, PTGES2 | HTT 227/4885ALDH1A1 866/4885KDM4E 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.